Cytokinetics (CYTK.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec19

Cytokinetics Incorporated's MYQORZO™ (aficamten) Receives FDA Approval

21:00

Cytokinetics Awaits FDA Decision on Aficamten

13:50

Dec17

Cellino Biotech's MYQORZO® Approved in China by NMPA

12:47

Dec16

Cellular Dynamics Executive Vice President Disposes of Common Stock

21:30

Dec12

Cytokinetics' MYQORZO® Recommended for Approval by EMA’s CHMP in Europe

13:43

Dec8

Cytokinetics Exec VP and CBO Andrew Callos Disposes of Common Stock

22:29

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.936 M, Net Income -306.18 M, EPS -2.5518

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 66.77 M, Net Income -134.37 M, EPS -1.1248

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 1.579 M, Net Income -161.38 M, EPS -1.3618

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change